At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction
In Brief
A Phase 2 clinical trial evaluating Vericiguat and Placebo for Metabolic Syndrome and Coronary Microvascular Dysfunction. Completed, enrolled 45 participants across 1 site.
Detailed Summary
Coronary vascular dysfunction is one of the "final common pathways" for the impact of multiple cardiovascular risk factors. The investigators will conduct a randomized, double-blind placebo-controlled study in individuals with the metabolic syndrome and baseline coronary vascular dysfunction to evaluate the impact of vericiguat, a stimulator of soluble guanylyl cyclase, on coronary vascular function using non-invasive cardiac magnetic resonance imaging.
Study Details
Timeline
Interventions
Up-titration will be performed as guided by the evaluation of blood pressure and clinical symptoms
Administered the same way